Overview
- Royal Marsden in London became the first European site to recruit a patient as global enrollment begins across more than 25 centres in seven countries.
- The study plans to enroll 280 men with early, localised prostate cancer who have already chosen surgical treatment.
- Aquablation uses a robotic high‑pressure waterjet with real‑time ultrasound mapping to remove cancerous tissue while avoiding nerves linked to bladder and erectile function.
- The trial is backed by the National Institute for Health and Care Research and sponsored by Procept BioRobotics, with UK sites at Royal Marsden, Guy’s and St Thomas’, the Royal Free London, and Norfolk and Norwich.
- In parallel, the UK National Screening Committee’s draft advice declines routine PSA population screening except for BRCA1/2 carriers, and Health Secretary Wes Streeting has said the decision will be reviewed as further evidence emerges within about two years.